-
1.发明申请公开(公告)号：US20150159148A1
公开(公告)日：2015-06-11
申请号：US14360573
申请日：2012-12-06
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Jeffrey Greve , John D. Mendlein
CPC classification number: C12N9/93 , A61K38/00 , A61K38/53 , A61K47/60 , C12N9/96 , C12Y601/01012 , C12Y601/01023 , Y02A50/411
Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
Abstract translation: 本发明提供聚乙二醇化天冬氨酰-tRNA合成酶（DRS）多肽，包含其的组合物，以及使用这些多肽和组合物治疗或诊断各种病症的方法。 与非聚乙二醇化DRS多肽相比，本发明的聚乙二醇化DRS多肽具有改善的控制释放性质，稳定性，半衰期和其他药代动力学性质。
-
公开(公告)号：US20140302075A1
公开(公告)日：2014-10-09
申请号：US14360576
申请日：2012-12-06
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Ryan Andrew Adams , Kristi Helen Piehl , Jeffrey Greve , John D. Mendlein
IPC: C12N9/00
CPC classification number: C12N9/93 , A61K38/00 , C07K2319/40 , Y02A50/411
Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
Abstract translation: 本发明提供具有改变的半胱氨酸含量的天冬氨酰-tRNA合成酶衍生蛋白（DRS多肽），包含其的组合物，以及使用这些多肽和组合物治疗或诊断各种病症的方法。 本发明的DRS多肽具有免疫调节特性，并表现出改进的活性和稳定性。
-
公开(公告)号：US10093915B2
公开(公告)日：2018-10-09
申请号：US15415369
申请日：2017-01-25
Applicant: aTyr Pharma Inc.
Inventor： Chi-Fang Wu , Darin Lee , Jeffry D. Watkins , Kristi Piehl , Kyle P. Chiang , Marc Thomas , Minh-Ha Do , Ying Buechler , John D. Mendlein
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
-
公开(公告)号：US09816084B2
公开(公告)日：2017-11-14
申请号：US14360576
申请日：2012-12-06
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Ryan Andrew Adams , Kristi Helen Piehl , Jeffrey Greve , John D. Mendlein
CPC classification number: C12N9/93 , A61K38/00 , C07K2319/40 , Y02A50/411
Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
-
公开(公告)号：US09587235B2
公开(公告)日：2017-03-07
申请号：US14214491
申请日：2014-03-14
Applicant: aTyr Pharma Inc.
Inventor： Ying Buechler , Kyle Chiang , Minh-Ha Do , Darin Lee , Kristi Piehl , Marc Thomas , Jeffry D. Watkins , Chi-Fang Wu , John D. Mendlein
CPC classification number: C12N9/93 , C07K2319/30 , C12N9/96 , C12Y601/01021
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
Abstract translation: 本发明提供组氨酰-tRNA合成酶和Fc区偶联物多肽（HRS-Fc缀合物），例如HRS-Fc融合多肽，包含其的组合物，以及使用这种缀合物和组合物治疗或诊断各种病症的方法。 本发明的HRS-Fc缀合物相对于相应的未修饰的HRS多肽具有改善的控制释放性质，稳定性，半衰期和其它药代动力学和生物学性质。
-
Patent Agency Ranking
公开(公告)号：US10711260B2
公开(公告)日：2020-07-14
申请号：US16577992
申请日：2019-09-20
Applicant: aTyr Pharma Inc.
Inventor： Chi-Fang Wu , Darin Lee , Jeffry D. Watkins , Kristi Piehl , Kyle P. Chiang , Marc Thomas , Minh-Ha Do , Ying Buechler , John D. Mendlein
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
-
公开(公告)号：US09822353B2
公开(公告)日：2017-11-21
申请号：US14360573
申请日：2012-12-06
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Jeffrey Greve , John D. Mendlein
CPC classification number: C12N9/93 , A61K38/00 , A61K38/53 , A61K47/60 , C12N9/96 , C12Y601/01012 , C12Y601/01023 , Y02A50/411
Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
-
公开(公告)号：US20170267990A1
公开(公告)日：2017-09-21
申请号：US15415369
申请日：2017-01-25
Applicant: aTyr Pharma Inc.
Inventor： Chi-Fang Wu , Darin Lee , Jeffry D. Watkins , Kristi Piehl , Kyle P. Chiang , Marc Thomas , Minh-Ha Do , Ying Buechler , John D. Mendlein
CPC classification number: C12N9/93 , C07K2319/30 , C12N9/96 , C12Y601/01021
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
-
公开(公告)号：US20140349369A1
公开(公告)日：2014-11-27
申请号：US14214491
申请日：2014-03-14
Applicant: aTyr Pharma Inc.
Inventor： Ying Buechler , Kyle Chiang , Minh-Ha Do , Darin Lee , Kristi Piehl , Marc Thomas , Jeffry D. Watkins , Chi-Fang Wu , John D. Mendlein
IPC: C12N9/00
CPC classification number: C12N9/93 , C07K2319/30 , C12N9/96 , C12Y601/01021
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
Abstract translation: 本发明提供组氨酰-tRNA合成酶和Fc区偶联物多肽（HRS-Fc缀合物），例如HRS-Fc融合多肽，包含其的组合物，以及使用这种缀合物和组合物治疗或诊断各种病症的方法。 本发明的HRS-Fc缀合物相对于相应的未修饰的HRS多肽具有改善的控制释放性质，稳定性，半衰期和其它药代动力学和生物学性质。
-
公开(公告)号：US11072787B2
公开(公告)日：2021-07-27
申请号：US16842200
申请日：2020-04-07
Applicant: aTyr Pharma Inc.
Inventor： Chi-Fang Wu , Darin Lee , Jeffry D. Watkins , Kristi Piehl , Kyle P. Chiang , Marc Thomas , Minh-Ha Do , Ying Buechler , John D. Mendlein
Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.168 seconds)
